Tacrolimus
| 證據等級: L5 | 預測適應症: 6 個 |
目錄
Tacrolimus: From Transplant Rejection Prevention to Seborrheic Dermatitis
One-Sentence Summary
Tacrolimus is a calcineurin-inhibiting immunomodulator classically used to prevent organ transplant rejection and, in topical form (Protopic), to treat atopic dermatitis. The TxGNN model predicts it may also be effective for Seborrheic Dermatitis, with 2 completed clinical trials (Phase 3 and Phase 4) and 20 supporting publications currently identified.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not specified in the evidence pack; tacrolimus is widely documented for prevention of organ transplant rejection (systemic) and atopic dermatitis (topical) |
| Predicted New Indication | Seborrheic Dermatitis |
| TxGNN Prediction Score | 99.26% |
| Evidence Level | L1 |
| Denmark Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the evidence pack. Based on widely known information, tacrolimus is a topical calcineurin inhibitor that suppresses antigen-specific T-cell activation and downregulates the inflammatory cytokine cascade — the same mechanism underlying its established efficacy in atopic dermatitis.
Seborrheic dermatitis and atopic dermatitis are both chronic inflammatory dermatoses that share T-cell–mediated inflammatory pathways and impaired skin barrier function; seborrheic dermatitis is additionally linked to Malassezia-driven inflammation. Because tacrolimus reduces local T-cell–mediated inflammation regardless of the triggering antigen, its mechanism plausibly extends from atopic dermatitis to seborrheic dermatitis.
This mechanistic rationale is directly supported by clinical evidence: two dedicated trials (a completed Phase 3 RCT and a completed Phase 4 study) have specifically evaluated tacrolimus ointment for maintenance treatment of severe facial seborrheic dermatitis in adults, reinforcing the plausibility of the TxGNN prediction.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT02004860 | Phase 3 | Completed | 120 | Evaluated tacrolimus ointment (Protopic) as maintenance therapy for severe seborrheic dermatitis on the adult face, aiming to reduce relapse frequency and steroid use |
| NCT01591070 | Phase 4 | Completed | 104 | Assessed whether proactive use of 0.1% tacrolimus ointment once or twice weekly maintains remission and reduces exacerbation in adult facial seborrheic dermatitis |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 33010323 | 2021 | RCT | J Am Acad Dermatol | Multicenter, double-blind RCT of tacrolimus 0.1% vs ciclopiroxolamine 1% for maintenance therapy in severe facial seborrheic dermatitis |
| 24171300 | 2013 | RCT | Ann Parasitol | Compared sertaconazole 2% cream vs tacrolimus 0.03% cream in 60 patients with seborrheic dermatitis |
| 39219446 | 2024 | Review (Cochrane) | Clin Exp Allergy | Network meta-analysis of topical anti-inflammatory treatments for eczema, relevant to calcineurin inhibitor efficacy/safety comparisons |
| 27804089 | 2017 | Systematic Review | Am J Clin Dermatol | Systematic review of topical treatments (antifungals, keratolytics, corticosteroids, TCIs) for facial seborrheic dermatitis |
| 19222250 | 2009 | Review | Am J Clin Dermatol | Reviews pathophysiology, safety, and efficacy of topical calcineurin inhibitors in seborrheic dermatitis |
| 19213227 | 2009 | Review | J Drugs Dermatol | Overview of facial seborrheic dermatitis status and therapeutic horizons, including TCIs |
| 15461548 | 2004 | Review | Expert Opin Pharmacother | Reviews tacrolimus ointment for atopic dermatitis and other inflammatory cutaneous disease, including seborrheic dermatitis |
| 26512166 | 2015 | Cohort | Ann Dermatol | Maintenance therapy of facial seborrheic dermatitis with 0.1% tacrolimus ointment |
| 37067129 | 2023 | Comparative Study | Indian J Dermatol Venereol Leprol | Compared oral itraconazole + topical tacrolimus vs topical tacrolimus alone for maintenance treatment of seborrheic dermatitis (Vietnam) |
| 12833030 | 2003 | Open Pilot Study | J Am Acad Dermatol | Open-label pilot study of 0.1% tacrolimus in 18 patients with seborrheic dermatitis; 61% achieved complete clearance |
Denmark Market Information
Tacrolimus currently has no marketing authorisation on file in Denmark (Laegemiddelstyrelsen) in this evidence pack — market status is Not marketed, with 0 authorisations recorded.
Safety Considerations
Please refer to the approved Summary of Product Characteristics (SmPC) for safety information.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Two completed clinical trials (Phase 3 and Phase 4) directly evaluate tacrolimus for facial seborrheic dermatitis maintenance treatment, supported by 20 publications including RCTs, systematic reviews, and cohort studies — meeting L1 evidence criteria. However, safety and Danish market data are entirely absent, so guardrails are required before advancing.
To proceed, the following is needed:
- Danish SmPC / Laegemiddelstyrelsen warnings, contraindications, and drug interaction data (currently a blocking data gap)
- Confirmed mechanism of action documentation from DrugBank
- Verification of a marketing pathway or existing authorisation in Denmark for tacrolimus (topical or systemic formulations)
- Formal route-of-administration compatibility assessment for the seborrheic dermatitis indication
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.